Neumora Therapeutics, Inc. (NMRA) Q1 2026 Earnings
NMRA·Reported May 7, 2026·After market close
Diluted EPS came in at $-0.30 (+28.6% YoY), beat the $-0.32 consensus by $0.02.
Diluted EPS
$-0.30beat by $0.02
Consensus: $-0.32
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Neumora Therapeutics, Inc.'s Q1 2026 earnings report.
Neumora Therapeutics, Inc. (NMRA) reported Q1 2026 earnings on May 7, 2026 after market close.
Neumora Therapeutics, Inc. reported diluted EPS of $-0.30 for Q1 2026.
EPS beat the consensus estimate of $-0.32 by $0.02.
Compared to the same quarter a year prior, diluted EPS grew 28.6% from $-0.42.
You can read the 8-K earnings release (0001193125-26-210310) and the 10-Q periodic report (0001193125-26-211825) directly on SEC EDGAR. The filing index links above go to sec.gov.